Frequency and type of cancers in myotonic dystrophy: A retrospective cross‐sectional study
Muscle & Nerve · 2023
DOI: 10.1002/mus.27801 ↗Kurz gefasst
Fachartikel in der Zeitschrift Muscle & Nerve, 2023. Verfasst von Eleonora S D'Ambrosio und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Myotonic Dystrophy, Muscular Dystrophy, Facioscapulohumeral, Melanoma. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, American Academy of Neurology, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
Introduction/Aims Myotonic dystrophies (DMs) are autosomal dominant diseases in which expression of a mutant expanded repeat mRNA leads to abnormal splicing of downstream effector genes thought to be responsible for their multisystem involvement. Cancer risk and cancer‐related deaths are increased in DM patients relative to the general population. We aimed at determining the frequency and type of cancers in both DM1 and DM2 vs a non‐DM muscular dystrophy cohort.
Methods
A retrospective, cross‐sectional study was carried out on patients with genetically confirmed DM1, DM2, facioscapulohumeral muscular dystrophy (FSHD), and oculopharyngeal muscular dystrophy (OPMD) at our institutions from 2000 to 2020.
Results
One hundred eighty‐five DM1, 67 DM2, 187 FSHD, and 109 OPMD patients were included. Relative to non‐DM, DM patients had an increased cancer risk that was independent of age and sex. Specifically, an increased risk of sex‐related (ovarian) and non–sex‐related (non‐melanoma skin, urological, and hematological) cancers was observed in DM1 and DM2, respectively. The length of CTG repeat expansion was not associated with cancer occurrence in the DM1 group.
Discussion
In addition to current consensus‐based care recommendations, our findings prompt consideration of screening for skin, urological, and hematological cancers in DM2 patients, and screening of ovarian malignancies in DM1 female patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
- Department of Neurology, Brigham Women's Hospital, Harvard Medical School, Boston, Massachusetts.
ORCID-Profile: Paloma Gonzalez-Perez
Förderung
- NINDS NIH HHS
- American Academy of Neurology
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
D'Ambrosio, E. S., Chuang, K., David, W. S., Amato, A. A., & Gonzalez-Perez, P. (2023). Frequency and type of cancers in myotonic dystrophy: A retrospective cross‐sectional study. Muscle & Nerve. https://doi.org/10.1002/mus.27801
Vancouver
D'Ambrosio ES, Chuang K, David WS, Amato AA, Gonzalez-Perez P. Frequency and type of cancers in myotonic dystrophy: A retrospective cross‐sectional study. Muscle & Nerve. 2023. doi:10.1002/mus.27801
BibTeX
@article{DAmbrosio2023,
author = {D'Ambrosio, Eleonora S and Chuang, Kathy and David, William S and Amato, Anthony A and Gonzalez-Perez, Paloma},
title = {Frequency and type of cancers in myotonic dystrophy: A retrospective cross‐sectional study},
journal = {Muscle & Nerve},
year = {2023},
doi = {10.1002/mus.27801}
}
EUVIMED